Ausgabe 6/2015
Inhalt (23 Artikel)
Antimitotic drugs in the treatment of cancer
Rustelle Janse van Vuuren, Michelle H. Visagie, Anne E. Theron, Annie M. Joubert
The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment
F. Jin, M. Robeson, H. Zhou, G. Hisoire, S. Ramanathan
Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors
Yutaka Fujiwara, Hiroshi Nokihara, Yasuhide Yamada, Noboru Yamamoto, Kuniko Sunami, Hirofumi Utsumi, Hiroya Asou, Osamu TakahashI, Ken Ogasawara, Ivelina Gueorguieva, Tomohide Tamura
A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors
Shinji Nakamichi, Hiroshi Nokihara, Noboru Yamamoto, Yasuhide Yamada, Kazunori Honda, Yosuke Tamura, Hiroshi Wakui, Tatsuya Sasaki, Wataru Yusa, Katsuki Fujino, Tomohide Tamura
Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients
Ping Liu, Ying Wang, Lina Tong, Yan Xu, Weihao Zhang, Zhi Guo, Hong Ni
Evodiamine inhibits the migration and invasion of nasopharyngeal carcinoma cells in vitro via repressing MMP-2 expression
Xianbing Peng, Qun Zhang, Yi Zeng, Jin Li, Lixin Wang, Ping Ai
A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients
Jose Francis, Biswajit Dubashi, Rajan Sundaram, Suresh Chandra Pradhan, Adithan Chandrasekaran
Evaluation of the safety and pathological effects of neoadjuvant full-dose gemcitabine combination radiation therapy in patients with biliary tract cancer
Shogo Kobayashi, Akira Tomokuni, Kunihito Gotoh, Hidenori Takahashi, Hirofumi Akita, Shigeru Marubashi, Terumasa Yamada, Teruki Teshima, Kinji Nishiyama, Masahiko Yano, Hiroaki Ohigashi, Osamu Ishikawa, Masato Sakon
Oxygen carrier YQ23 can enhance the chemotherapeutic drug responses of chemoresistant esophageal tumor xenografts
Nikki P. Lee, Kin Tak Chan, Mei Yuk Choi, Ho Yu Lam, Lai Nar Tung, Fei Chuen Tzang, Heron Han, Ian P. Y. Lam, Sui Yi Kwok, Sze Hang Lau, Cornelia Man, Daniel K. Tong, Bing L. Wong, Simon Law
Effect of pH adjustment by mixing steroid for venous pain in colorectal cancer patients receiving oxaliplatin through peripheral vein: a multicenter randomized phase II study (APOLLO)
Taishi Hata, Michitaka Honda, Michiya Kobayashi, Akihiro Toyokawa, Masahiro Tsuda, Yukihiko Tokunaga, Kozo Takase, Masakazu Miyake, Satoshi Morita, Naoki Nagata, Junichi Sakamoto, Masahiko Gosho, Hideyuki Mishima
Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer
Tatsuya Kurihara, Mari Kogo, Masakazu Ishii, Ken Shimada, Keiichiro Yoneyama, Katsuya Kitamura, Shunichi Shimizu, Hitoshi Yoshida, Yuji Kiuchi
Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer
Haruko Daga, Koji Takeda, Hideaki Okada, Masaki Miyazaki, Shinya Ueda, Hiroyasu Kaneda, Isamu Okamoto, Kiyotaka Yoh, Koichi Goto, Koichi Konishi, Akiko Sarashina, Tetsuya Tanaka, Rolf Kaiser, Kazuhiko Nakagawa
Local transdermal therapy to the breast for breast cancer prevention and DCIS therapy: preclinical and clinical evaluation
Oukseub Lee, David Ivancic, Subhashini Allu, Ali Shidfar, Kara Kenney, Irene Helenowski, Megan E. Sullivan, Miguel Muzzio, Denise Scholtens, Robert T. Chatterton Jr., Kevin P. Bethke, Nora M. Hansen, Seema A. Khan
Impact of ER520, a candidate of selective estrogen receptor modulators, on in vitro cell growth, migration, invasion, angiogenesis and in vivo tumor xenograft of human breast cancer cells
Lijun Wang, Ying Wang, Huaqing Du, Yao Jiang, Zhichao Tang, Hongyi Liu, Hua Xiang, Hong Xiao
Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma
Matthew D. Galsky, Noah M. Hahn, Bryan Wong, Karen M. Lee, Pamela Argiriadi, Costantine Albany, Kiev Gimpel-Tetra, Nancy Lowe, Mohamed Shahin, Vaibhav Patel, Che-Kai Tsao, William K. Oh
Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study
Young Saing Kim, Sun Jin Sym, Min Young Baek, Inkeun Park, Junshik Hong, Hee Kyung Ahn, Jinny Park, Eun Kyung Cho, Woon Ki Lee, Min Chung, Hyung-Sik Kim, Jae Hoon Lee, Dong Bok Shin
Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors
Elizabeth Fox, Brigitte C. Widemann, Devang Pastakia, Clara C. Chen, Sherry X. Yang, Diane Cole, Frank M. Balis
Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction
Maarten J. Deenen, Didier Meulendijks, Henk Boot, Marie-Cecile J. C. Legdeur, Jos H. Beijnen, Jan H. M. Schellens, Annemieke Cats
Analysis of redox and apoptotic effects of anthracyclines to delineate a cardioprotective strategy
Joy Marie Fulbright, Daniela E. Egas-Bejar, Winston W. Huh, Joya Chandra
Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer
Zheng Wu, Andrew Gabrielson, Jimmy J. Hwang, Michael J. Pishvaian, Louis M. Weiner, Tingting Zhuang, Lisa Ley, John L. Marshall, Aiwu Ruth He
Schedule-dependent modulation of the pharmacokinetics of MK-2206, an oral pan-AKT inhibitor: perspectives
Nuggehally R. Srinivas
Erlotinib-related rhabdomyolysis: the role of pharmacogenetics and drug–drug interaction
Marta Koršić, Davorka Muršić, Sonja Badovinac, Nada Božina, Mihovil Roglić, Marko Jakopović, Branka Čučević